Invitrogen Up Almost 11 Percent on BioReliance Sale, EPS Performance

Feb 14, 2007

NEW YORK (GenomeWeb News) — Shares in Invitrogen were up nearly 10.5 percent at $66.73 in mid-afternoon trading after the company reported yesterday it would sell its flagging BioReliance business, and that its fourth-quarter earnings per share beat Wall Street expectations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

More to Do

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

To Control the Spread

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

This Week in PLOS

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

'Follow Me to Maryland'

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.

Main menu